NCT01611272

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,402 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 19 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.

Detailed description

A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta

Conditions

• Acute Coronary Syndromes

Timeline

• Start date: 2013-04-30
• Primary completion: 2016-07-20
• Completion: 2016-07-20
• First posted: 2012-06-04
• Last updated: 2017-07-13

Locations

23 sites across 1 country: South Korea